Beulah Biomedics

Beulah Biomedics is a Melbourne-based biotechnology company dedicated to the development of first-in-class treatments for chronic inflammatory and fibrotic diseases. The company was established to commercialize breakthrough research from the University of Melbourne and St. Vincent's Institute of Medical Research. Its core intellectual property centers on small molecule inhibitors designed to block the biological pathways responsible for organ scarring. In 2018, Beulah's assets were transitioned into Certa Therapeutics following a significant investment round to accelerate clinical development. The lead candidate, originally developed by Beulah, is now being evaluated in mid-stage clinical trials for kidney and lung diseases. The company's approach focuses on precision medicine to identify patients most likely to respond to its anti-fibrotic therapies.